|
|
|
A new study from researchers at the University of Michigan Rogel Cancer Center sheds light on the KRAS pathway with a potential target that might have more success at stopping lung cancer growth.
|
Media contact: Nicole Fawcett, 734-764-2220 | Patients may contact Cancer AnswerLine™, 800-865-1125
ANN ARBOR, Mich. — One day, a pancreatic cancer patient will provide a blood sample and doctors will recommend treatments designed to target all the harmful cell’s in the individual’s tumor. This is the vision of pancreatic cancer researchers at the University of Michigan Rogel Cancer Center.
|
Researchers at the University of Michigan Rogel Cancer Center analyzed the global landscape of a portion of the genome that has not been previously well-explored. This analysis opens the door to discovery of thousands of potential new cancer biomarkers.
|
Media contact: Nicole Fawcett, 734-764-2220 | Patients may contact Cancer AnswerLine, 800-865-1125
ANN ARBOR, Mich. – New research from the University of Michigan Rogel Cancer Center helps explain why pancreatic cancer is so lethal, with fewer than a third of patients surviving even early stage disease.
|
A new study characterizes the genetic underpinnings of a rare type of breast tumor called phyllodes tumors, offering the first comprehensive analysis of the molecular alterations at work in these tumors.
|
|
One of the mysteries in cancer biology is how one protein, TGF-beta, can both stop cancer from forming and encourage its aggressive growth. Now, researchers at the University of Michigan Rogel Cancer Center have uncovered a key gene that may explain this paradox and provide a potential target for treatment.
|
|
|